Company: IPSC
Filing Date: 2025-07-07
Form Type: 8-K
Source: 0001104659-25-066091
Chunk: 1

Company: Century Therapeutics, Inc.
Filing Date: 2025-07-07
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements  

Departure of Chief Financial Officer and Chief Development Officer

In connection with the RIF, on July 1, 2025, the Board approved the
departure of Morgan Conn, Ph. D. from his position as the Company’s Chief Financial Officer, effective July 11,
2025 and Adrienne Farid, Ph. D. from her position as the Company’s Chief Development Officer, effective July 31, 2025. Each such departure will be a termination without Cause as defined in the executive Employment Agreement between the Company and each
executive, dated September 20, 2024 and May 26, 2021, respectively.

Appointment of Interim Principal Financial Officer

Following the effectiveness of Dr. Conn’s departure from the
Company, Douglas Carr, the Company’s Senior Vice President, Finance, will serve as interim Principal Financial Officer.

SIGNATURES